

2026-2027 Strategic plan overview

March 2026

QBiotics Group

Disclaimer

This presentation has been prepared by QBiotics Group Limited ACN 617 596 139 (QBiotics or the Company) and contains summary information about QBiotics and the business conducted by it as at the date of this presentation. The information in this presentation is for general purposes only, does not purport to be complete or comprise all information required by shareholders or investors to make an informed decision on any investment in QBiotics. The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of QBiotics in any jurisdiction, including the United States. In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change. This presentation may contain forward-looking statements concerning the Company's business, operations, financial performance and condition as well as the Company's plans, objectives and expectations for its business, operations, financial performance and condition. Any statements that are not of historical facts may be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which the Company operates and management's beliefs and assumptions. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties, assumptions and other factors that are in some cases beyond the Company's control. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. As a result, any or all of the Company's forward-looking statements in this presentation may turn out to be inaccurate.

Introduction

QBiotics Group Limited (QBiotics) has developed a portfolio of differentiated first-in-class small molecule therapeutics, derived from its proprietary epoxytigliane platform.

These programmes target significant unmet medical needs across:

Oncology – Phase II

Wound healing – Phase I

Antibiotics – Discovery

Our strategy is to advance these programmes to Phase II proof-of-concept, generating clinically meaningful data to support pharmaceutical partnering.

Our current focus is our unique oncology drug, tigilanol tiglate which is partner ready.

3

Accelerating maturity to commercialisation

QBiotics' strategy is built on three Strategic Pillars that define key priorities, driving accountability, sharpening focus on near-term oncology partnerships, and accelerating execution

Cash

Capital efficiency and disciplined execution

Customers

Pharma-aligned, de-risked asset creation

Culture

Frequent transparent communications with shareholders and Accountability

Strategic Priorities that stem from our Pillars

Cash

1. **Strengthen the financial position:** complete a capital raise to provide sufficient runway to achieve a commercial oncology deal that can underpin a liquidity event
2. **Prudent capital deployment:** reduce cash burn to extend runway to negotiate an oncology deal

Customers

1. **Secure oncology partnerships:** secure a collaboration or licensing agreement, leveraging 2026 clinical data across multiple tumour types including breast cancer, foundational science and strong patents
2. **Progress wound healing partnerships and funding:** complete current trial and initiate partnering discussions
3. **Transition veterinary oncology commercialisation:** transition STELFONTA® to a new global distribution partner, optimising commercial performance across the USA,EU, UK, Australia, and selected Asian markets, to drive improved revenue

Culture

1. **Improve shareholder communication:** increase the frequency and business content of transparent communication on progress against the Priorities
2. **Ensure accountability:** conduct regular reviews to ensure accountability
3. **Maintain compliance:** maintain our public company compliance posture
4. **Renew focus:** keep the team laser focused on the Strategic Priorities and ensure execution
5. **Prioritise lean governance:** ensure the Board is similarly focused, lean and engaged on the right things at a Pillar and Priorities level

Robust data foundation for confident clinical development

- ✓ Treatment regime close to optimal
- ✓ Safety & efficacy demonstrated
- ✓ Easy to use usually single injection
- ✓ Local & systemic effect
- ✓ GMP API and drug product commercially viable
- ✓ 5 year stability 2-8ºC
- ✓ 18 month stability 25ºC
- ✓ Source plant commercial plantations established
- ✓ 2nd Generation program already in development to address eventual patent cliff

Vet product STELFONTA™

Regulatory, CMC and commercial validation

Memorial Sloan Kettering Cancer Center — STS Phase II - 81% injected tumour ORR FDA ODD

ROYAL MARSDEN NHS Foundation Trust — H&NC Phase II - *data under analysis*

unicancer GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS — Phase II Breast Cancer – *trial in process*

MALIC Paris Marie-Lannelongue Innovation Center — VX2 Rabbit liver model – *study in process*

Significant potential for Pharma Partner

- ✓ External and potentially internal tumours
- ✓ Monotherapy
- ✓ In combination with ICI drugs and chemotherapy

Large Markets

EMA FDA Veterinary Medicines Directorate Australian Government Australian Pesticides and Veterinary Medicines Authority

Sources: Lumanity, 2022. Evaluation of tigilanol tiglate in soft tissue sarcoma I Lumanity, 2022. Opportunity assessment for tigilanol tiglate in melanoma and head and neck cancer I Ramskov Consulting, 2024. Review of soft tissue sarcoma I Global new cases: Global Cancer Observatory, Globocan 2022 I Zhou et al., 2025. Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer. Scientific Reports. I Global Data, 2022

QBiotics Group

Tigilanol tiglate: Derisked Phase II partner ready

Pharma partner criteria	
Large market opportunity across multiple indications	✓ Demonstrated safety and strong efficacy in local treatment of a range of tumour types in human clinical trials and case studies ○ Phase IIa investigator-led (Unicancer, France) breast cancer study in a large market with significant unmet need – in process ✓ Preliminary evidence (preclinical & clinical) of effects on systemic disease ○ Extension of Phase II soft tissue sarcoma study to further characterise systemic effects ✓ Confirmation of mode of action shown in patient-derived tissue samples ○ Selection underway of second-generation molecule to create future value for partner ○ Animal liver cancer model to evaluate opportunity for treatment of visceral tumours
Extensively reduced development risk – mature toxicology, CMC / manufacturing program, demonstration of efficacy	✓ Demonstrated safety and efficacy in a broad range of tumour types ✓ Demonstration of reliable supply chain and commercially-scalable production methods ✓ Mature toxicology studies allow progression into Phase III human clinical studies ○ Further optimisation of dosing in cost-effective, real-world veterinary models ✓ Multi-jurisdictional registration of STELFONTA® as a veterinary oncology drug
Strong intellectual property position and freedom to operate	✓ Initial composition of matter and use patent ✓ New Patents strengthen IP position and patent terms ➢ Use in combination therapies (ICIs, chemotherapeutics, radiotherapy) ➢ Immune priming effects ➢ Manufacturing method for API
Independent validation of technology	✓ Grant of FDA Orphan Drug status ✓ Publication of preclinical and clinical data in peer-reviewed scientific journals ✓ Internationally-recognised Clinical Advisory Board ✓ Internationally-recognised Scientific Advisory Board ○ Regulatory meetings – FDA Type C; EMA Scientific Advice

Thank you

communications@qbiotics.com
www.qbiotics.com

QBiotics Group